

# Kamalram Thippu Jayaprakash

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1061257/publications.pdf>

Version: 2024-02-01

33  
papers

43  
citations

1937685  
4  
h-index

1872680  
6  
g-index

34  
all docs

34  
docs citations

34  
times ranked

68  
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes in the Management of Patients having Radical Radiotherapy for Lung Cancer during the First Wave of the COVID-19 Pandemic in the UK. <i>Clinical Oncology</i> , 2022, 34, 19-27.	1.4	7
2	A High-Throughput In Vitro Radiobiology Platform for Megavoltage Photon Linear Accelerator Studies. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 1456.	2.5	0
3	Spleen as an organ at risk in lower lobe lung tumours treated with radical radiotherapy. <i>Lung Cancer</i> , 2022, 165, S60.	2.0	0
4	Assessment of the impact of SARS-CoV-2 PCR results amongst thoracic oncology patients. <i>Lung Cancer</i> , 2022, 165, S11.	2.0	0
5	Shooting the Star: Mitigating Respiratory Motion in Lung Cancer Radiotherapy. <i>Clinical Oncology</i> , 2022, 34, 160-163.	1.4	0
6	Harmonisation of radiotherapy practice in lung cancer: East of England Regional Radiotherapy Network Initiative. <i>Lung Cancer</i> , 2022, 165, S7.	2.0	0
7	Notch Inhibition: a Promising Strategy to Improve Radiosensitivity and Curability of Radiotherapy. <i>Clinical Oncology</i> , 2021, 33, e44-e49.	1.4	6
8	In Vitro Evaluation of Notch Inhibition to Enhance Efficacy of Radiation Therapy in Melanoma. <i>Advances in Radiation Oncology</i> , 2021, 6, 100622.	1.2	3
9	Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e042953.	1.9	15
10	Identification of a microbiome signature predicting immune checkpoint inhibitor outcomes across multiple cancer types in the MITRE study. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS2665-TPS2665.	1.6	0
11	Changes in management for patients with lung cancer referred for radical radiotherapy during the first wave of the COVID 19 pandemic in the UK (COVID-RT Lung). <i>Lung Cancer</i> , 2021, 156, S14.	2.0	0
12	Minimising radical Radiotherapy Commencement time for Lung cancer to improve clinical outcomes (MIRACLE). <i>Lung Cancer</i> , 2021, 156, S57.	2.0	0
13	A case of non-small cell lung cancer with EGFR exon 20 insertion treated with osimertinib. <i>Lung Cancer</i> , 2021, 156, S73-S74.	2.0	0
14	PO-1198 Changes in radical radiotherapy for lung cancer patients in the UK during the COVID-19 pandemic. <i>Radiotherapy and Oncology</i> , 2021, 161, S994-S995.	0.6	0
15	Metastatic prostate cancer men's attitudes towards treatment of the local tumour and metastasis evaluative research (IP5-MATTER): protocol for a prospective, multicentre discrete choice experiment study. <i>BMJ Open</i> , 2021, 11, e048996.	1.9	2
16	Management of lung cancer in patients with interstitial lung disease. <i>Lung Cancer</i> , 2020, 139, S87-S88.	2.0	0
17	A dosimetric comparison of radical radiotherapy techniques in non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 139, S37-S38.	2.0	1
18	OC-0449: Pre-clinical evaluation of combining radiation with Notch signalling inhibition in melanoma. <i>Radiotherapy and Oncology</i> , 2020, 152, S248-S249.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Initial experience of the adjuvant treatments to the local tumor for metastatic prostate cancer: Assessment of novel treatment algorithms, a multicenter, phase II randomized controlled trial (IP2-ATLANTA).. Journal of Clinical Oncology, 2020, 38, TPS5600-TPS5600.	1.6	1
20	Neutrophil-to-lymphocyte ratio (NLR) trends and treatment response to programmed death/ligand 1 (PD-1/PD-L1) inhibitors in non-small cell lung cancer (NSCLC). Lung Cancer, 2019, 127, S41-S42.	2.0	1
21	Rare double mutations in epidermal growth factor receptor (EGFR) mutant adenocarcinoma of lung. Lung Cancer, 2019, 127, S92-S93.	2.0	0
22	EP-2311: Biological effects of radiation dose-rate and intra-fraction breaks in stereotactic radiotherapy. Radiotherapy and Oncology, 2018, 127, S1275-S1276.	0.6	0
23	EP-2312: Biological validation of a high-throughput in-vitro radiobiology platform. Radiotherapy and Oncology, 2018, 127, S1276-S1277.	0.6	0
24	115P Heart and pulmonary artery radiation doses in non-small cell lung cancer. Journal of Thoracic Oncology, 2018, 13, S63-S64.	1.1	0
25	PO-0990: Combining radiotherapy and notch inhibition in melanoma. Radiotherapy and Oncology, 2017, 123, S546-S547.	0.6	0
26	Feasibility of Hippocampal Avoidance Radiotherapy for Glioblastoma. Clinical Oncology, 2017, 29, 748-752.	1.4	4
27	The role of oncologists in management decisions for non-metastatic muscle invasive bladder cancer (MIBC). Clinical Oncology, 2016, 28, S2.	1.4	0
28	138 Stage I non small cell lung cancer (NSCLC): single centre comparison of outcome by treatment with surgery, conventional radiotherapy and stereotactic ablative radiotherapy. Lung Cancer, 2016, 91, S50.	2.0	0
29	Pelvic Nodal Irradiation (PNRT) in Prostate Cancer: Cambridge Experience. Clinical Oncology, 2016, 28, e12-e13.	1.4	0
30	Benefits of Stereotactic Radiotherapy Fellowships to Clinical Oncology Trainees. Clinical Oncology, 2016, 28, e221.	1.4	0
31	Unilateral neck radiotherapy for tonsillar squamous cell carcinomas. Clinical Oncology, 2016, 28, S12.	1.4	0
32	Improving Clinical Oncology Trainees' Radiotherapy Induction. Clinical Oncology, 2016, 28, e220.	1.4	1
33	EP-1706: Evaluation of different radiosurgical planning techniques using iPlan®. Radiotherapy and Oncology, 2016, 119, S797-S798.	0.6	0